Latigo Biotherapeutics (LTGO) stock

Pain medicines , market cap $1.1B

Non-opioid pain medicines

Market cap $1.1B

$15.26

+1.60%

As of Monday's close · Live for Pro members at the open

Quality Score

-1

Poor

In its industry

#154of 291

Biotech

Checks firing

3of 14

Trending down

From its high

-41.1%

No 200-day yet

LTGO's Quality Score rose 1 point on Mon, Oct 26, to -1. Closed near the day's high.

New listing, trading since Aug 7, 2026. 56 trading days so far, so 4 of the 14 chart checks wait for more history.

Follow LTGO's trial news. Pro members can get an alert when Latigo Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when LTGO files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2H 2027“…results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027…”Trial data · SEC filing · Sep 3

Key facts on LTGO

Key facts on LTGO
Holding it back	32.2% more shares than a year ago
Latest filing	10-Q, Sep 3 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind LTGO's -1, for Pro members.

LTGO catalysts

Coming up

After its last report it closed +2.5%.

1 past catalyst since 2026, with sizes and sources, for Pro members.Get in free →

What's next for LTGO, and how long its cash lasts

Next step the company has named

2H 2027“Expect to report topline results from the Phase 3 bunionectomy and open-label safety clinical trials in the second half of 2027.”Trial data · SEC filing · Sep 3

What it means: the first look at a trial’s main results, as the company reports them.

1 more trial, 2 filings, for Pro members.

Cash runway Jun 30 balance sheet

$55M in cash

Fewer than four quarters of cash flow are on file.

What it means: a runway is counted only when each of the last four quarters used cash. The company's estimate is “into 2029” (8-K, Sep 3). It has raised money since that balance sheet, which is not counted here.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director James B. Tananbaum bought 140,000 shares on Aug 10.

From Form 4: open-market buys and sales only.

Get an alert when Nima Farzan buys or sells

For Pro members: every trade, and Nima Farzan’s 2 filings and quotes.

Get an alert when LTGO files news on its trialSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 15 daysANDA decisionIn 15 days · ANDA decisionNRXPNRX PharmaceuticalsPreservative-free ketamineNRXPNRX Pharmaceuticals · $104MPreservative-free ketamineA generic, under FDA review (GDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $356MDeramiocelFDA decision due (PDUFA)
In 27 daysFDA decisionIn 27 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $933MMolgramostimFDA decision due (PDUFA)

10 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 168 dates, ranked →

Why LTGO scores -1

PoorTrending down, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
−2Dilution 32.2% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.

No effect today: Long-term trend, Run-up, Size, Profit, Growth, Cash flow, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on LTGO and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:26 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when LTGO's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on LTGO and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

LTGO has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on LTGO, and all 14 on every stock.Get in free →

LTGO RSI today: 42.8, below its 50-day average

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1442.8
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 3 sessions ago.
50-day average$19.34
The price is 21.1% below it.
200-day average
Not enough history yet.
50/200 cross
Not enough history yet.
ADX 1429.4
25 or more, with +DI below -DI.
Support$13.50
Swing low from Oct 15, 11.5% below the price.
Resistance$24.80
Swing high from Sep 17, 62.5% above the price.
High since listing$25.93
From Aug 27, 69.9% above the price.
Low since listing$13.50
From Oct 15, 11.5% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $13.66 to $17.72.
Volume0.5x
Against its 20-day average, for the time of day.

The deep dive on LTGO

What it does and how it makes money1 findingFor Pro members1 finding on what LTGO does and how it makes money, for Pro members
Where it stands1 findingFor Pro members1 finding on where LTGO stands: its cash, debt, and share count, for Pro members
Who holds and trades it3 findings10% owner James B. Tananbaum bought $2.52M of shares on the open market on Aug 10, 2026, the only insider trade in 90 days.Form 4, filed Aug 10, 2026

4 more findings on LTGO, each with its source, for Pro membersGet in free →

How LTGO ranks in Biotech

LTGO is #154 of 291 by Quality Score.

How LTGO ranks in Biotech
1	HALOHalozyme Therapeutics	9/14	21
2	AMRXAmneal Pharmaceuticals	9/14	20
3	RIGLRigel Pharmaceuticals	9/14	19
	LONALeonaBio		Open for its score
	LRMRLarimar Therapeutics		Open for its score
	LXEOLexeo Therapeutics		Open for its score
	LXRXLexicon Pharmaceuticals		Open for its score
154	LTGOLatigo Biotherapeutics	3/14	-1

When does LTGO report earnings, and what happens after?

Expected to report Thu Nov 12, after the close (in 17 days). Expected.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

+2.5%

Sep 3

Reported	When	Gap	Reaction	5 sessions
Sep 3, 2026After close	After close	+0.9%	+2.5%	-1.5%

LTGO closed higher after 1 of its last 1 report.

LTGO share count over time

Shares: 32.2% more than a year ago (to Jun 30).

Shares of LTGO outstanding, as filed
Shares outstanding	As of
66.3M	Sep 1, 2026

Offerings, shelves, and splits of LTGO, from its filings
From its filings	Filed
Raised $345.6M in a sale of shares, about 31% of its market value	Aug 7, 2026
Registered shares for sale (S-1)	Jul 17, 2026

Who is trading LTGO

LTGO insider trades

One insider bought $2.5M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyJames B. Tananbaum$2.5M10% ownerat $18.00 on Aug 10, filed Aug 10

BuyJames B. Tananbaum10% owner$2.5Mat $18.00 on Aug 10, filed Aug 10

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Thousand Oaks, CAlatigobio.com

Listed on Nasdaq on Aug 7, 2026, and is 15% below its $18 offer price now. Its IPO filing and first days

LTGO's score card

Latigo Biotherapeutics (LTGO): Quality Score -1, Poor, #154 of 291 in Biotech, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn LTGO's score around: 4 things
2 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayAug 10James B. Tananbaum bought LTGO$2.5M at $18.00, filed Aug 10

Alerts are optional.

See LTGO's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Oct 26, 2026: LTGO's Quality Score is -1 (Poor), #154 of 291 in Biotech. Insiders bought $2.5M in the last 6 months (Form 4).

Is LTGO a good stock to buy? What its Quality Score says

LTGO scores -1 today, which Breakaway calls Poor. It is #154 of 291 in Biotech by Quality Score, with 3 of 14 chart checks firing. Shares: 32.2% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is LTGO's Quality Score?

LTGO scores -1 today, which Breakaway calls Poor (below zero). That is #154 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind LTGO's -1.

Are insiders buying LTGO?

One insider bought $2.5M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is James B. Tananbaum, 10% owner, who bought $2.5M on Aug 10.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.